ANAB AnaptysBio, Inc.

+0  (1%)
Previous Close 24.74
Open 25.00
Price To book 0.00
Market Cap 503.32M
Shares 20,173,000
Volume 66,319
Short Ratio 2.50
Av. Daily Volume 159,622

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a trial initiated 1Q 2017 with data due 2H 2017.
Moderate-to-severe adult atopic dermatitis
Phase 2a trial to be initiated 1H 2017 with data due 1H 2018.
Severe adult eosinophilic asthma
Phase 2a trial initiated 1Q 2017 with data due 2H 2017.
Severe adult peanut allergy

Latest News

  1. AnaptysBio, Inc. – Value Analysis (NASDAQ:ANAB) : April 20, 2017
  2. AnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : April 19, 2017
  3. AnaptysBio Announces First-In-Human Dosing of ANB019
  4. ETFs with exposure to AnaptysBio, Inc. : April 5, 2017
  5. Will Snap, MuleSoft IPOs Kick Up A Stampede Of Tech Unicorns?
  6. AnaptysBio, Inc. :ANAB-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  7. AnaptysBio, Inc. :ANAB-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
  8. AnaptysBio Announces 2016 Operating Results and Pipeline Progress
  9. AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting
  10. Biotech IPOs Slow As Trump-Sown Uncertainty Rattles Nerves On Wall Street
  11. AnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings
  12. Robust Start for Pharmaceutical IPOs In 2017
  13. ($$) Braeburn Pharmaceuticals Puts IPO Plans On Hold
  14. AnaptysBio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  15. ($$) Shares in Two Biotechs Rise Post-IPO
  16. IPO Market Looking for 7 Offerings This Week
  17. After $97M IPO, Swiss biotech to open U.S. headquarters in Boston
  18. ​Cambridge’s Jounce raises hopes as first Mass. biotech of 2017 to go public
  19. AnaptysBio Announces Pricing of Initial Public Offering